The Scout
Longevity deal intelligence for funds and family offices. Domain-deep. Category-only. Integrated with our IR practice.
Our filter
Scientific validity
01
Anything we surface has been read by domain analysts. Hype dressed in scientific language gets filtered out before you see it.
Founder readiness
02
If the founder cannot translate the science to a non-scientific investor in real time, the deal is not ready. We send it back to The Studio side first.
Commercial logic
03
Long cycles, regulated channels, scientific gatekeepers. Companies surfaced for your fund have a model that respects the category.
Capital fit
04
Round size that matches your fund's mandate. We do not surface deals you cannot write.
And one final criterion behind these four: at least one Blue analyst would put their own money in. If that is not true, the deal does not get surfaced.
Find yourself?
Who we work with
We are additive to a fund or family office that has longevity (or longevity-adjacent: metabolic health, healthtech, biotech) within its mandate. We do not take mandates from generalist funds without category conviction — the math does not work for either side. Capacity is capped. Mandates are by application.